Targeted alpha therapy (TAT) is the delivery of high-energy alpha particles to cancer cells and the tumour microenvironment to treat cancer. After a survival benefit was shown for radium-223 versus standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC), radium-223 became the first approved TAT.1–3 In the European Society for Medical Oncology (ESMO) […]
Trending Topic
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies and the evolving understanding of complex malignancies. We open with an editorial by Mohammad Ammad […]
Journal Archive
Comprising articles contributed by renowned thought leaders, European Oncology & Haematology is a peer reviewed, free-to-access, bi-annual journal that aims to disseminate best practice through review articles addressing the most important and salient developments in the Oncological & Haematology field in practical terms.
European Oncology & Haematology
Frequency: Two print issues per year (Summer & Winter); ePub ahead of print throughout the year.
Print ISSN: 2045-5275 Electronic ISSN: 2045-5283
Indexing: EMBASE, Google Scholar, Genamics JournalSeek
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
